Treatment persistence and compliance with medications for chronic obstructive pulmonary disease
about
Ten years of tiotropium: clinical impact and patient perspectivesPrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Management of asthma and chronic obstructive pulmonary disease with combination inhaled corticosteroids and long-acting β-agonists: a review of comparative effectiveness research.The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.Treatment evolution after COPD diagnosis in the UK primary care setting.Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasoneCharacteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study.Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease.Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD - real-life experience from an observational study.Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting β₂-agonists: a dispensing database analysisFrequency and risk factors of COPD exacerbations and hospitalizations: a nationwide study in Greece (Greek Obstructive Lung Disease Epidemiology and health ecoNomics: GOLDEN study).Optimizing safety of COPD treatments: role of the nurse practitioner.Health behaviors and their correlates among participants in the Continuing to Confront COPD International Patient Survey.Safety, tolerability and risk benefit analysis of tiotropium in COPD.A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost.Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial.Diagnosis and management of asthma in older adults.Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax® compared with Turbuhaler® in patients with moderate-to-severe chronic obstructive pulmonary disease in SPersistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.The pharmacological approach to the elderly COPD patient.Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study.Incidence, Predictors, and Clinical Implications of Discontinuing Therapy with Inhaled Long-Acting Bronchodilators among Patients with Chronic Obstructive Pulmonary Disease.Factors associated with medication adherence in patients with chronic obstructive pulmonary disease.Describing drivers of and barriers to persistence with tiotropium in patients with chronic obstructive pulmonary disease: a mixed-methods approach.Adherence and Persistence to Long-Acting Anticholinergics Treatment Episodes in Patients With Chronic Obstructive Pulmonary Disease.Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD).Tiotropium as part of inhaled polytherapy: adherence and associated health-care utilization.Determinants of Long-Term Persistence with Tiotropium Bromide for Chronic Obstructive Pulmonary Disease.A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom.Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD)
P2860
Q26823682-5A996EBA-018E-4CE5-8F09-F7C4328100DDQ27348844-D984FF95-D593-430E-8CAD-377A500DB641Q33646667-F3F7B13A-6223-4182-8AE4-87AF15C3AE14Q33966009-76C2106C-4129-4EA9-BB07-27C2A6AAEBD6Q34121263-4305ED7F-9DAD-486F-8855-DBF1C3C4D15BQ34128947-D717EBDF-097A-43A3-8B0B-8742F2F3C845Q34273638-26171A01-A157-4C02-A202-8B2C3EB4EB72Q35205369-A9B4EB91-2DE8-4D6E-923A-47B2176045AFQ35208787-28DDCEB3-AD7B-44DC-ADC1-414224D9F474Q35216376-FECF70F1-36AA-489B-98D5-08B2FD87BCF3Q36390652-12D72FC4-183B-408B-B222-0DB57BCC3280Q36642198-B5216666-5C95-4DDB-9A0D-ACBD2F9087F8Q36858219-A2E28EA8-3C72-4A50-AEED-5F00882C6AA1Q37115876-5B6973BE-A51A-49B1-8C78-3D44B9A1E919Q37133820-6979C46A-2CA6-4A09-B50A-EAE3745BD559Q37310689-F490C7B6-E85F-4FFB-B84D-95ADB0FAEC37Q37340845-4376A6A4-632F-49B3-85E1-16FFFAEDA7C9Q37502960-7E5F57B0-130A-4E23-88B5-150D1835097DQ37645807-6C0B73D9-7F4E-428E-B42F-B55A2CF2C7A0Q37864717-45B22370-969D-4AC3-8252-9398A082AF36Q38098479-EAFD41A7-8E25-4F3E-83C3-1D914D63EFCFQ38819989-5BA0CC95-5516-495C-A4E5-A3B29C487448Q40876442-A9407B0A-EEF2-4B1B-B913-D9D2A6F3ED39Q43744795-F99683D9-5851-485B-A514-ADBB4493C5B4Q46831428-90DE490A-51BF-4B26-84E6-0E8724D6E5EDQ47816402-566C68FA-EF1D-4316-BE91-CFD00E858577Q47911959-5BED289F-58D0-4522-8740-0E4FDE4D48B9Q50601223-7A23BD5C-3655-49F1-8986-05749A0F0103Q51706078-BA471EB2-592E-417F-877C-865DC96B9746Q51725664-76CCE692-DB67-4C7B-B4C3-C6FAC2AE06BFQ57809552-8341ABDD-0E7A-4D0A-AF74-2F677168D1A4
P2860
Treatment persistence and compliance with medications for chronic obstructive pulmonary disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment persistence and comp ...... obstructive pulmonary disease
@en
Treatment persistence and comp ...... obstructive pulmonary disease.
@nl
type
label
Treatment persistence and comp ...... obstructive pulmonary disease
@en
Treatment persistence and comp ...... obstructive pulmonary disease.
@nl
prefLabel
Treatment persistence and comp ...... obstructive pulmonary disease
@en
Treatment persistence and comp ...... obstructive pulmonary disease.
@nl
P2093
P2860
P356
P1476
Treatment persistence and comp ...... obstructive pulmonary disease
@en
P2093
Alissa Scalera
Carole Bradley-Kennedy
Joyce A Cramer
P2860
P356
10.1155/2007/161652
P407
P577
2007-01-01T00:00:00Z